PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DX21FNVQC4554906120!perjeta 420 MG 14 ML VIAL 14ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DX15D9239. PoP ended Oct 7, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Dms Pharmaceutical Group Inc
Recipient
Oct 7, 2021
PoP end
$166K
Obligated
$166K
Potential
424210
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal
Contract numberSPE2DX21FNVQC
Also listed asSPE2DX15D9239-SPE2DX21FNVQC
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentDms Pharmaceutical Group Inc
CAGE1UNB0
UEIPX72BSBQTKJ3
NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DX15D9239
Place of performancePARK RIDGE IL
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 16, 2021
PoP end (current)Oct 7, 2021
Obligated$166K
Current value$166K
Potential value$166K

4554906120!PERJETA 420 MG/14 ML VIAL 14ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $166K ($166K obligated). Current period of performance ends Oct 7, 2021. Place of performance: PARK RIDGE IL.

4554906120!PERJETA 420 MG/14 ML VIAL 14ML

Recompete timing

Public
● Past PoP end (1779 days ago)

Current PoP ended Oct 7, 2021 (1779 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies
Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%
Open full company profile →

Related awards

Same parent · incumbent
SPE2D026F0120
8511978882!OTHER MEDICAL
$248K
Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract SPE2DX21FNVQC?

SPE2DX21FNVQC (4554906120!perjeta 420 MG 14 ML VIAL 14ml) is a Dla Troop Support award with a potential value of $166K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DX21FNVQC?

Dla Troop Support awarded SPE2DX21FNVQC to Dms Pharmaceutical Group Inc (potential $166K).

Who is the incumbent on SPE2DX21FNVQC?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Oct 7, 2021.

When does Dms Pharmaceutical Group Inc’s SPE2DX21FNVQC come up for recompete?

SCOUT tracks a period-of-performance end of Oct 7, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DX21FNVQC